2025
Burden and care time for dementia caregivers in the LIVE@Home.Path trial
Berge L, Angeles R, Gedde M, Fæø S, Mannseth J, Vislapuu M, Puaschitz N, Hillestad E, Aarsland D, Achterberg W, Allore H, Ballard C, Li F, Selbæk G, Vahia I, Husebo B. Burden and care time for dementia caregivers in the LIVE@Home.Path trial. Alzheimer's & Dementia 2025, 21: e14622. PMID: 40042468, PMCID: PMC11881633, DOI: 10.1002/alz.14622.Peer-Reviewed Original ResearchConceptsRelative Stress ScaleInformal care timeCaregiver burdenLiving interventionsCare timeIntervention periodStepped wedge randomized controlled trialVolunteer supportHome-dwelling peopleStepped-wedge trialPersonal activitiesDementia caregiversRandomized controlled trialsIntention-to-treatStress ScaleMunicipal coordinatorCaregiversPersonal supportRandomized dyadsDementiaControlled trialsPrimary outcomeControl periodInterventionPositive changes
2024
Prepare Romania: study protocol for a randomized controlled trial of an intervention to promote pre-exposure prophylaxis adherence and persistence among gay, bisexual, and other men who have sex with men
Lelutiu-Weinberger C, Filimon M, Zavodszky A, Lixandru M, Hanu L, Fierbinteanu C, Patrascu R, Streinu-Cercel A, Luculescu S, Bora M, Filipescu I, Jianu C, Heightow-Weidman L, Rochelle A, Yi B, Buckner N, Golub S, van Dyk I, Burger J, Li F, Pachankis J. Prepare Romania: study protocol for a randomized controlled trial of an intervention to promote pre-exposure prophylaxis adherence and persistence among gay, bisexual, and other men who have sex with men. Trials 2024, 25: 470. PMID: 38987812, PMCID: PMC11238350, DOI: 10.1186/s13063-024-08313-4.Peer-Reviewed Original ResearchConceptsGBMSM livingPrEP adherenceRandomized controlled trial designMobile health interventionsRollout of PrEPMonths post-randomizationPre-exposure prophylaxisPre-exposure prophylaxis adherenceSelf-report surveyRandomized controlled trialsPromotion interventionsPrescribed PrEPEfficacy of toolsHealth interventionsNational rolloutHealth systemPrEP rolloutDiscussionThe knowledgeIntervention efficacyEffectiveness trialBlood spot testingPost-randomizationHigh-risk groupHIV transmissionDried blood spot testingRationale and Design of a Phase 2, Double-blind, Placebo-Controlled, Randomized Trial Evaluating AMP Kinase-Activation by Metformin in Focal Segmental Glomerulosclerosis
Barsotti G, Luciano R, Kumar A, Meliambro K, Kakade V, Tokita J, Naik A, Fu J, Peck E, Pell J, Reghuvaran A, Tanvir E, Patel P, Zhang W, Li F, Moeckel G, Perincheri S, Cantley L, Moledina D, Wilson F, He J, Menon M. Rationale and Design of a Phase 2, Double-blind, Placebo-Controlled, Randomized Trial Evaluating AMP Kinase-Activation by Metformin in Focal Segmental Glomerulosclerosis. Kidney International Reports 2024, 9: 1354-1368. PMID: 38707807, PMCID: PMC11068976, DOI: 10.1016/j.ekir.2024.02.006.Peer-Reviewed Original ResearchMinimal change diseaseRandomized controlled trialsSafety of metforminDouble-blindPodocyte injuryAdjunctive therapyPlacebo-controlled randomized controlled trialsPhase III studyPhase II trialPrimary glomerular diseaseFocal segmental glomerulosclerosisEffect of metforminPhase IIPlacebo-controlledPreclinical dataNovel urineChange diseaseTissue markersRandomized trialsSegmental glomerulosclerosisGlomerular diseaseMechanistic biomarkersObservational studyFSGSInexpensive agent
2023
R ealtime Diagnosis from E lectrocardiogram Artificial Intelligence- G uided Screening for A trial Fibrillation with L ong Follow-Up (REGAL): Rationale and design of a pragmatic, decentralized, randomized controlled trial
Yao X, Attia Z, Behnken E, Hart M, Inselman S, Weber K, Li F, Stricker N, Stricker J, Friedman P, Noseworthy P. R ealtime Diagnosis from E lectrocardiogram Artificial Intelligence- G uided Screening for A trial Fibrillation with L ong Follow-Up (REGAL): Rationale and design of a pragmatic, decentralized, randomized controlled trial. American Heart Journal 2023, 267: 62-69. PMID: 37913853, DOI: 10.1016/j.ahj.2023.10.005.Peer-Reviewed Original ResearchConceptsConsumer wearable devicesOlder adultsUnrecognized AFAssociated with increased risk of strokeApple WatchFollow-upAtrial fibrillationAssociated with increased riskEarly diagnosis of AFAll-cause mortalityRandomized controlled trialsCognitive function declineEarly diagnosisIntervention armPragmatic trialRisk of strokeDiagnosis of AFAI-ECGDisease preventionSecondary outcomesFunctional declineDisease burdenPrimary outcomeLong-term follow-upHigh-risk patients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply